On Monday, Silence Therapeutics plc SLN presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L).These data were presented at the American Heart Association (AHA) Scientific Sessions.Results showed that zerlasiran (300 mg every 16 weeks, 300 mg every 24 weeks or 450 mg every 24 weeks) produced greater than 80% mean time-averaged placebo-adjusted reductions from baseline in ...

Exhibit 99.1 Condensed consolidated income statement (unaudited) | --- | --- | --- | --- | --- | |---------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|------------------------------------------------------------|--------------------------------------------------------| | £000s (except per share information) | Three months ended \nSeptember 30, 2024 \n£000s | Three months ended \nS ...

Pathompong Thongsan/iStock via Getty Images Silence Therapeutics plc (NASDAQ:SLN) develops RNA interference ("RNAI") therapies that silence genes associated with various diseases. SLN employs its proprietary mRNAi GOLD platform to produce short interfering RNAs (siRNAs) that degrade disease-related mRNA. It focuses especially on genes expressed in the liver, which is an ideal target due to its essential role in metabolism and regulating proteins, fats, and carbohydrates. Currently, SLNCF's main drug candida ...

andresr/E+ via Getty Images The last time I wrote about Silence Therapeutics plc (NASDAQ:SLN) it was in a Seeking Alpha article entitled "Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results." With this article, I noted that the company had already released positive results using one of its small interfering RNA [siRNA] candidates, known as zerlasiran. This is for the treatment of patients with elevated levels of Lp[a] at high risk of atherosclerotic cardiovascular disease [ASCVD]. ...

Exhibit 99.1 Condensed consolidated income statement (unaudited) | --- | --- | --- | --- | --- | |---------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|------------------------------------------------------|--------------------------------------------------| | £000s (except per share information) | Three months ended \nJune 30, 2024 \n£000s | Three months ended \nJune 30, 2023 \n£000s | Six ...

Last month, the company announced positive data from the ongoing phase I repeat dose SANRECO study on its pipeline candidate, divesiran (SLN124) for treating patients with polycythemia vera. Treatment with divesiran was generally well-tolerated and eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing. This might have driven the share price rally. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) s ...

Risks To Business A third risk to consider would be regarding the partnership with AstraZeneca that had been done to advance siRNA drug candidate for the treatment of patients with cardiovascular, renal, metabolic and respiratory diseases. Thus far, Silence Therapeutics was able to receive $10 million from the collaboration agreement because of the nomination of one candidate. The ability to obtain additional milestone payments is going to depend upon whether other candidates are ultimately nominated. There ...

Silence Therapeutics plc (NASDAQ:SLN) Q4 2023 Earnings Conference March 13, 2024 8:00 AM ET Company Participants Gem Hopkins - Head of Investor Relations & Corporate Communications Craig Tooman - President & Chief Executive Officer Rhonda Hellums - Chief Financial Officer Steven Romano - Head of R&D Conference Call Participants Mike Ulz - Morgan Stanley Kostas Biliouris - BMO Capital Markets Patrick Trucchio - H.C. Wainwright Keay Nakae - Chardan Research Operator Good day, and thank you for standing by. We ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Full Year 2023 Conference Call March 13, 2024 Forward-Looking Statements 2 The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in certain jurisdictions may be restricted by law, and persons into whose possession this presentation comes should inform themselves about, and observe, any such ...